HUTCHMED (China) Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HCM research report →
Companywww.hutch-med.com
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
- CEO
- Chig Fung Cheng
- IPO
- 2016
- Employees
- 1,811
- HQ
- Hong Kong, HK
Price Chart
Valuation
- Market Cap
- $2.08B
- P/E
- 4.56
- P/S
- 4.70
- P/B
- 1.70
- EV/EBITDA
- -856.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 18.62%
- Op Margin
- -2.64%
- Net Margin
- 104.77%
- ROE
- 41.38%
- ROIC
- -0.69%
Growth & Income
- Revenue
- $549.96M · -12.73%
- Net Income
- $458.12M · 1114.23%
- EPS
- $2.65 · 1101.81%
- Op Income
- $-54,725,352
- FCF YoY
- -353.16%
Performance & Tape
- 52W High
- $19.50
- 52W Low
- $11.83
- 50D MA
- $14.08
- 200D MA
- $14.84
- Beta
- 0.38
- Avg Volume
- 30.90K
Get TickerSpark's AI analysis on HCM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Mok Tony Shu Kam | other | 0 |
| Mar 31, 26 | Nixon Charles George Rupert | other | 0 |
| Mar 31, 26 | Nixon Charles George Rupert | other | 0 |
| Dec 11, 19 | Nixon Charles George Rupert | other | 400,000 |
| Apr 28, 20 | Nixon Charles George Rupert | other | 57,720 |
| Dec 14, 20 | Nixon Charles George Rupert | other | 3,395 |
| Mar 26, 21 | Nixon Charles George Rupert | other | 31,620 |
| Dec 14, 21 | Nixon Charles George Rupert | other | 4,087 |
| May 23, 22 | Nixon Charles George Rupert | other | 7,015 |
| Jun 5, 23 | Nixon Charles George Rupert | other | 4,520 |
Our HCM Coverage
We haven't published any research on HCM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HCM Report →